All News
Doctor Appointment Wait TImes are Up
Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.
Read Article
First In Class, TYK2 Inhibitor FDA Approved for Psoriasis
Deucravacitinib (Sotyktu), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.
Read Article
Taiwan population study shows increased all-cause mortality for psoriasis patients (HR 1.16; 1.13-1.19) vs. general population. https://t.co/p09mXTfXPw https://t.co/UVK3GMMmip
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 247 consecutive PsA pts shows that two-thirds (63.15%) had poor sleep quality. Poorer sleep was assoc w/ being female, higher joint counts, greater peripheral and axial disease activity, but fatigue & anxiety most explained poor sleep quality https://t.co/RTZqxtyIu9 https://t.co/OVtTQkFirD
Links:
Dr. John Cush RheumNow ( View Tweet)
Secukinumab retention in PsA: Study of 170 pts, 13% B27+, most w/ peripheral arthritis &70% on 150 mg/mo. Median retention 636 days. Peripheral arthritis was a predictor of better retention (HR 0.424). https://t.co/aZD9qD0jxm https://t.co/FlqRlcAZd1
Links:
Dr. John Cush RheumNow ( View Tweet)
The Atlantic has published an insightful article on "Brain Fog", especially as a Long Covid consequence (IMHO: Brain fogs primary cause is poor sleep, fibromyalgia, chronic fatigue - but can be complication to primary CNS events) https://t.co/SlwzRDSVSf https://t.co/qrBvV5oyUA
Links:
Dr. John Cush RheumNow ( View Tweet)
Doctor Appointment Wait Times are Up
Forbes reports that a recent Merritt Hawkins survey shows that patients are waiting an average of 26 days for a scheduled appointment with a doctor.
https://t.co/oJkLRzRR1y https://t.co/8zy0LgC7dt
Links:
Dr. John Cush RheumNow ( View Tweet)
TYK2 Inhibitor FDA Approved for Psoriasis
BMS made a mega bet on deucravacitinib, an in-house experimental TYK2 drug, in the leadup to the big Celgene buyout, keeping it while auctioning off Celgene’s top-selling Otezla to Amgen for $13.4 billion
https://t.co/wPN62jBIvL https://t.co/Cj6svOoiaJ
Links:
Dr. John Cush RheumNow ( View Tweet)
I created an online version of the Modified Rodnan Skin Score (mRSS) to make it easier to calculate
References mentioned below tool:
https://t.co/5Us3usCTsC
@SindhuJohnson5 @Janetbirdope
#scleroderma #rheum #rheumatology
A Omar ahomar ( View Tweet)
Nice table from the Poddubny et al., (2021) study which looks at some of the different characteristics between Axial SpA vs Axial PsA.
Axial PsA tends to have;
- Less frequent IBP
- Less HLAB27 +‘ve
- More frequent C-spine involvement https://t.co/XXQKBSfSQq
Charlie Clements ClementsCharl96 ( View Tweet)
In your RHEUMATOLOGY practice how often are you seeing #LongCovid (new fatigue,brainfog,breathless etc) in your immune dis pts with COVID ( i.e. > 1 month) @CCalabreseDO @jeffsparks @zach_wallace_md @philipcrobinson @JYazdanyMD @alhkim @RheumNow @EBRheum @rheum_cat @AWIRGROUP
Leonard Calabrese LCalabreseDO ( View Tweet)
The ACR is developing a new clinical practice guideline for systemic autoimmune rheumatic disease with interstitial lung disease (ILD). The Call for Public Comment is open until September 29, 2022. https://t.co/UxXDbGEQlh https://t.co/zGoBpbKLTC
Links:
Dr. John Cush RheumNow ( View Tweet)
A longitudinal study of 506 ANCA-associated vasculitis (AAV) pts showed pts w/ negative ANCA serologies within 180 days of induction had signif lower risk of relapse (HR 0.55; 0.38 to 0.81) but not for ESRD or death within 5 years. https://t.co/Dn8GGXnSDi https://t.co/C73hG9T7Au
Links:
Dr. John Cush RheumNow ( View Tweet)
Immunosuppresive (IST; MMF or AZA) withdrawl in 96 stable Lupus Nephritis pts also on HCQ. After 2 years, Relapse occurred in 12.5% w/ IST continued & 27.3% with IST D/C (Not noninferior). Less Severe SLE flares (renal & extrarenal) w/ IST continuation https://t.co/XWmJpkqhG9 https://t.co/gYM24QIiYz
Links:
Dr. John Cush RheumNow ( View Tweet)
COVID Outcomes in Dermatomyositis
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
https://t.co/nlCVHt3XeS https://t.co/Bhc47k7rMD
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Fibromyalgia Need B12?
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news.
https://t.co/ztDVHfGegM https://t.co/ux4F0UIIld
Links:
Dr. John Cush RheumNow ( View Tweet)
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/xchK5ETmg3 https://t.co/F9klsUE5er
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 130 patients with ITP (w/ 10 later Dx SLE (30 mos F/U). Risk factors for ITP developing SLE included young age (< 40yrs; OR 6.3), organ bleeding (OR 13.7), and ANA (≥ 1:160; OR 6.6) https://t.co/o9sO5WQmcq https://t.co/6RrrKzu41p
Links:
Dr. John Cush RheumNow ( View Tweet)
Voclosporin Efficacy and Safety in Lupus Nephritis
An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.
https://t.co/WqQ7wdzmCc https://t.co/uxFb6Nbdgi
Links:
Dr. John Cush RheumNow ( View Tweet)
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/wCyZjRbWe8 https://t.co/U0LlDnuNtZ
Links:
Dr. John Cush RheumNow ( View Tweet)